Novartis/Schering Vatalanib NDA Delayed Until 2007; Misses Primary Endpoint
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Novartis/Schering AG Re-Evaluating PTK/ZK Due To Low Probability Of Survival Benefit
Novartis and Schering AG plan to re-evaluate their development strategy for PTK/ZK 787 (vatalanib) following an interim analysis showing a low probability of a survival benefit in the second-line metastatic colorectal cancer setting
Novartis Plans Three NME Filings In 2005, Including First Oral VEGF Inhibitor
Novartis plans three NME filings in 2005, including first oral VEGF agent, firm says during Jan. 20 R&D day. PTK787 has blockbuster potential in colorectal cancer, Novartis says. Nine more NME filings are scheduled for next two years
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011